Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Latest advances in cardiovascular medicine, science and education to be presented at AHA 2011

Perelman School of Medicine at the University of Pennsylvania faculty will be involved in presenting research findings on the latest advances in cardiovascular medicine, science, and education at the 2011 American Heart Association Scientific Sessions, in Orlando, FL, November 12 - 16, 2011.

14 Nov 2011

Salt – is it bad for the heart? Debate continues

Salt or high sodium intake in diet has drawn attention of researchers for a while now. The U.S. Food and Drug Administration held a day-long hearing today, discussing strategies to help Americans cut the salt from their diets as a latest attempt to curb sodium in the American diet.

13 Nov 2011

Research roundup: Cutting speciality care by raising co-payments; Asthma diagnosis and insurance coverage; GAO on early retirees

Mayo Clinic Employees Responded To New Requirements For Cost Sharing By Reducing Possibly Unneeded Health Services Use -- Researchers at the Mayo Clinic examined the effects of changes in the clinic's self-funded health plan "to decrease the use of potentially inappropriate health care services and foster a deliver system centered on primary care."

11 Nov 2011

Stroke warning signs need more urgent attention

Patients who suffer stroke-like attacks can have mortality rates 20 per cent higher than the general population, new research finds, leading to calls for better stroke prevention strategies for those who experience a transient ischemic attack (TIA).

10 Nov 2011

AOK selects SAP HANA platform to increase focus on preventive care

SAP AG today announced that AOK, Germany's largest health insurance provider, has chosen the SAP HANA platform to further its focus on preventive care.

10 Nov 2011

Treatments can help most HCM patients

Most of the 600,000 Americans with hypertrophic cardiomyopathy (HCM) -- a genetic heart muscle disease -- can live normal life spans, according to the first science-based guideline for diagnosing and treating this disorder.

9 Nov 2011

Highmark now covers AlloMap for monitoring heart transplant rejection

XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive diagnostic tests to monitor immune-mediated conditions, today announced that Highmark Inc., an independent licensee of the Blue Cross Blue Shield Association, is now covering AlloMap for its beneficiaries.

9 Nov 2011

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis.

8 Nov 2011

Thoratec board authorizes repurchase of additional $50M of common stock

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that its Board of Directors has authorized the repurchase of an additional $50 million of the company's shares of common stock over the next year.

7 Nov 2011

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the Phase 3 ABILITY-1 study of HUMIRA (adalimumab) in patients with active non-radiographic axial spondyloarthritis.

7 Nov 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

Abbott today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA (adalimumab) plus methotrexate (MTX) for up to eight years in patients with early moderate to severe rheumatoid arthritis (RA) and up to 10 years in patients with long-standing moderate to severe RA, respectively.

7 Nov 2011

RA patients with low levels of inflammation less likely to develop cardiovascular disease

According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, patients with rheumatoid arthritis who have low levels of inflammatory disease activity have lower risk for heart complications and stroke.

7 Nov 2011

$New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout$

New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout

Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.

7 Nov 2011

Medtronic highlights scientific sessions of interest on program for TCT 2011

Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.

From Medtronic 5 Nov 2011

NCQA recognizes three additional MetCare centers as PPC-PCMH

Metropolitan Health Networks, Inc., a leading provider of health care services in Florida, today announced that an additional three of its centers have been recognized by the National Committee for Quality Assurance (NCQA) as Physician Practice Connections - Patient-Centered Medical Homes.

5 Nov 2011

Miracor's PICSO system safe and feasible during elective PCI

Miracor Medical Systems announced today that data will be reported during next week's "TCT (Transcatheter Cardiovascular Therapeutics) 2011" scientific meeting in San Francisco.

5 Nov 2011

Acorda third quarter GAAP net income increases to $18.9 million

Acorda Therapeutics, Inc. today announced its financial results for the third quarter ended September 30, 2011.

4 Nov 2011

AMAG reports third quarter total revenues of $17.6 million

AMAG Pharmaceuticals, Inc. today reported unaudited consolidated financial results for the third quarter ended September 30, 2011.

4 Nov 2011

CRF summit to examine importance of gender in cardiovascular disease research

"In Pursuit of Excellence: Improving Cardiovascular Outcomes in Women" will be held on Friday Dec. 9, 2011. The meeting, which will bring together top national experts in research, academia, and health policy to examine the importance of gender in cardiovascular disease research, will take place at The Princeton Club in New York City. Roxana Mehran, MD will Chair this important meeting.

4 Nov 2011